Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

The Orthohantavirus GN/GC Spikes: Molecular Determinants of Infection and Targets for Antiviral Immune Interventions.

Created on 08 Jul 2026

Authors

Gianina Arata-Salas, Dianne Díaz-Ramírez, Benjamín E Vásquez, Benjamín Zamorano-Godoy, Paulina S Rubilar, Nicole D Tischler

Published in

Annual review of virology. Jul 07, 2026. Epub Jul 07, 2026.

Abstract

Orthohantaviruses are globally distributed, rodent-borne RNA viruses associated with severe and often lethal disease in humans. The documented person-to-person transmission of Andes virus, endemic in South America, underscores their pandemic potential, and yet no effective treatments are available, while vaccines exist only for Hantaan and Seoul viruses. Key targets for antiviral intervention are the tetrameric GN/GC spikes, which are displayed on the viral surface. Here we review current molecular and cellular insights into these spikes, focusing on their roles during the viral infection cycle, such as receptor-mediated cell entry, membrane fusion, viral assembly, and cell exit. We also examine recent advances in therapeutic antibody developments and identify structurally conserved immune hotspots linked with their possible inhibitory mechanism. Finally, we discuss progress in GN/GC-based vaccine research and clinical trials, highlighting key achievements and remaining challenges to overcome the public health threat posed by orthohantaviruses.

PMID:
42412999
Bibliographic data and abstract were imported from PubMed on 08 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement